

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel in the order listed for Form Page 2.
Follow the sample format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME		POSITION TITLE	
Beringer, Paul M.		Associate Professor of Clinical Pharmacy and Clinical Medicine	
EDUCATION/TRAINING (begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)			
INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
University of Southern California	PharmD	1990	Pharmacy

A. Positions and Honors.**Positions and Employment**

1990-1991 Pharmacy Practice Residency, UCSF School of Pharmacy
 1991-1992 Specialty Residency in Clinical Pharmacokinetics, UCSF
 1992-2000 Assistant Professor of Clinical Pharmacy, USC School of Pharmacy
 2000- Associate Professor of Clinical Pharmacy, USC School of Pharmacy
 2001- Associate Professor of Clinical Medicine, Dept. Pulmonary and Critical Care Medicine, Keck School of Medicine
 2001- Associate Director for Research, Adult CF Center, Keck School of Medicine.

Other Experience and Professional Memberships

1995- Board Certified Pharmacotherapy Specialist (BCPS)
 1998-99 Network Facilitator on Pharmacokinetics, American Society of Health-System Pharmacists
 1999 President, Southern California College of Clinical Pharmacy
 2001 President, Southern California Society of Health-System Pharmacists
 2002 Chair, Practitioner Recognition Awards Committee California Society of Health-System Pharmacists

Honors

1995 Practitioner Fellow, American Society of Health-System Pharmacists

B. Selected publications (in chronological order).

Beringer PM, Rho JP. Comparing the newest fluoroquinolones: Levofloxacin and sparfloxacin *Formulary* 1997;32:926-43.

Wong-Beringer A, **Beringer PM**, Lovett MA. Successful treatment of meningitis due to multi-drug resistant *Pseudomonas aeruginosa* with high-dose ciprofloxacin therapy. *Clin Infect Dis* 1997;25:936-7.

Beringer PM, Wong-Beringer A, Rho JP. Economic aspects of antibacterial adverse effects. *PharmacoEconomics* 1998;13:35-49.

Beringer PM, Vinks A, Jelliffe R. Pharmacokinetics of once-daily amikacin dosing in patients with cystic fibrosis. [letter] *J Antimicrob Chemother* 1998;41:142-44.

Beringer PM, Wong-Beringer A, Rho JP. Predictive performance of a vancomycin-aminoglycoside population model. *Ann Pharmacother* 1998;32:176-81.

Beringer PM. New Approaches to optimizing antimicrobial therapy in patients with cystic fibrosis. *Curr Opinion Pulm Med* 1999;5:371-77.

Beringer PM, Vinks A, Jelliffe R, Shapiro B. Pharmacokinetics of tobramycin in adults with cystic fibrosis: Implications for once-daily administration. *Antimicrob Agents Chemother* 2000;44:809-813.

Montgomery MJ, **Beringer PM**, Louie SG, Gill MA. Estimation of creatinine clearance in patients with metastatic ovarian cancer receiving peritoneal chemotherapy. *Ther Drug Monitor* 2000;22:695-700.

Beringer PM. Unusual microbiological flora in cystic fibrosis lungs: identification and therapy. *Curr Opinion Pulm Med* 2000;6:545-550.

Aminimanizani A, **Beringer PM**, Jelliffe R. Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone agents. *Clin Pharmacokinet* 2001;40:169-87.

Beringer PM. The clinical use of colistin in patients with cystic fibrosis. *Curr Opinion Pulm Med* 2001;7:434-40.

Montgomery MJ, **Beringer PM**, Aminimanizani A, Louie SG, Shapiro B, Jelliffe R, Gill MA. Population Pharmacokinetics and use of Monte Carlo simulation to determine the optimal dose of ciprofloxacin in adult patients with cystic fibrosis. *Antimicrob Agents Chemother* 2001;45:3468-73.

Beringer PM, Aminimanizani A, Scott C, Synold T. Development of population pharmacokinetic models and optimal sampling times for ibuprofen in children with cystic fibrosis. *Ther Drug Monitor* 2002;24:315-21.

C. Research Support

Ongoing Research Support

Co-Investigator - Epidemiological study of cystic fibrosis (ESCF). Genentech. January 2000 – January 2003.

Principal Investigator – Pharmacodynamics of continuous infusion cefepime in adult cystic fibrosis patients. Dura Pharmaceuticals. March 2000 – July 2003

Co-Investigator – Evaluation of the absorption characteristics of oral linezolid during continuous enteral feedings. Pharmacia-Upjohn. December 2000 – December 2002

Principal Investigator – Bactericidal activity of ampicillin-sulbactam, gatifloxacin, and their combination against carbapenem resistant isolates of *Acinetobacter baumannii*. Bristol Myers Squibb. March 2002- March 2003.

Principal Investigator – Bioavailability and intracellular pharmacokinetics of azithromycin in adult patients with cystic fibrosis. Webb-Berger Research Award. January 2002 – December 2002.

Co-investigator - Paradoxical effects of Ritonavir on P-glycoprotein and Cytochrome P450 3A4 and 2C8 expression: Regulation by Orphan Nuclear Factor, Steroid Xenobiotics Receptor (SXR). American Society of Health System Pharmacists Foundation Basic Science-Applied Therapeutics Research Grant. January 2002 – December 2002.

Completed Research Support

Principal Investigator - Comparative pharmacokinetics of a tablet and extemporaneous liquid formulation of lamotrigine. Glaxo-Wellcome. May 1998 - August 1998.

Principal Investigator - Population pharmacokinetics of intravenous ciprofloxacin in adult cystic fibrosis patients. Bayer Pharmaceuticals. November 1998 December 2000.

Principal Investigator - Pharmacokinetics of ‘once-daily’ tobramycin in adult cystic fibrosis patients. Abbott Diagnostics. December 1998 – December 2000.